Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Psoriatic Arthritis
- Enrollment Status: Open
- Protocol: I1F-MC-RHDE
- Drug: tirzepatide/ ixekizumab
- Sponsor: Eli Lilly
- Description: A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide after Initiation of Ixekizumab in Adult Participants with Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice